--- title: "Petrelintide: Research & Side Effects | BodyHackGuide" url: https://www.bodyhackguide.co/compound/petrelintide description: "Petrelintide: mechanism, clinical studies & side effects." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) # Petrelintide Metabolic & Weight Loss: https://www.bodyhackguide.co/wiki#cat-metabolic-&-weight-loss Status Phase 3 (ZUPREME-3, ZUPREME-4 and ZUPREME-5, recruiting on ClinicalTrials.gov on 27 Oct...,, not approved for human use Evidence Not graded on a research bench yet Petrelintide (ZP8396) is an investigational once-weekly injectable analogue of the pancreatic hormone amylin, developed by Zealand Pharma, that activates amylin receptors and the calcitonin receptor and is in phase 3 trials for weight management. Reviewed 4 November 2026 01 Overview ## What Petrelintide is In the phase 2 ZUPREME 1 trial of 493 adults with obesity or overweight and no type 2 diabetes, mean body weight fell 7.9 to 9.8 percent from baseline across five petrelintide doses at 28 weeks against 1.7 percent with placebo, and nausea was the most common adverse event, in 20 percent against 6 percent (PMID: 42810355). Zealand Pharma funded the published trials, and ClinicalTrials.gov lists Hoffmann-La Roche as sponsor, with Zealand Pharma as collaborator, of the three phase 3 petrelintide trials (PMID: 42810355, PMID: 42017294; ClinicalTrials.gov NCT07843498, NCT07843485, NCT07843472). Petrelintide is not approved by the FDA: Drugs@FDA returned no record for petrelintide on 27 October 2026. ### How it works ### Amylin, the hormone petrelintide copies Amylin is a pancreatic beta-cell hormone released together with insulin. It contributes to blood glucose control after meals, slows gastric emptying, suppresses glucagon secretion and promotes satiation through actions in the brain (PMID: 42586227). Amylin activates amylin receptors with high potency and the calcitonin receptor with lower potency; the three amylin receptor subtypes form when the calcitonin receptor pairs with one of three receptor activity-modifying proteins (RAMPs) (PMID: 41217931). Read the full mechanism Show less Natural human amylin is short-acting, forms amyloid fibrils and degrades in solution (PMID: 41217931). Pramlintide, the first amylin analogue approved by the FDA, in 2005, avoided fibrils by borrowing proline residues from rat amylin, must be formulated at acidic pH, and needs several injections a day because of its short half-life (PMID: 41217931). ### How petrelintide was designed (laboratory data) A 2025 paper by scientists at Zealand Pharma, with coauthors from Boehringer Ingelheim, describes the design (PMID: 41217931). Starting from human amylin, the team added N-methyl groups to glycine 24 and isoleucine 26, in the region that drives fibril formation, instead of using prolines (PMID: 41217931). The chemists deleted asparagines 21 and 22 and replaced other asparagines, which are prone to chemical breakdown (deamidation), to make the peptide stable at neutral pH (PMID: 41217931). The team also replaced the disulfide bridge between positions 2 and 7, which let pairs of molecules join into dimers, with an amide (lactam) bridge, and the analogues in the program carry a 20-carbon diacid attached through a gamma-glutamic acid linker at the N-terminus to extend their half-life (PMID: 41217931). Peptide 40 in the paper, the compound selected, was later named petrelintide (PMID: 41217931). Under accelerated conditions of up to 1 month at 40 degrees Celsius, petrelintide formed no fibrils and no substantial covalent oligomers in common buffers at pH 6.1 to 7.4 (PMID: 41217931). Coformulated with semaglutide (https://www.bodyhackguide.co/compound/semaglutide) at about neutral pH and stored for 4 weeks at 40 degrees Celsius, petrelintide's rate of chemical breakdown did not change substantially and neither peptide aggregated, which the authors present as support for coformulation with other peptide drugs (PMID: 41217931). ### Receptor activity (cell data) In COS7 cells engineered to express the human calcitonin receptor alone or together with RAMP3 (the amylin 3 receptor), petrelintide raised cyclic AMP with an EC50 of 0.33 nM at the amylin 3 receptor and 0.32 nM at the calcitonin receptor; human amylin gave 0.51 nM and 3.5 nM in the same assays (PMID: 41217931). The phase 1 report describes petrelintide as a potent agonist at the amylin 1 and amylin 3 receptors and at the calcitonin receptor (PMID: 42017294), and a 2026 review groups petrelintide with cagrilintide (https://www.bodyhackguide.co/compound/cagrilintide) as a dual amylin and calcitonin receptor agonist (DACRA) (PMID: 42452898). ### Animal data In lean rats, a single injection under the skin gave a plasma half-life of 33.8 hours and a body weight reduction of about 10 percent 96 hours later (PMID: 41217931). In diet-induced obese rats injected every second day for 20 days, petrelintide lowered food intake in a dose-dependent way; at the highest dose, cumulative food intake by day 20 was 298 g per rat against 390 g with vehicle, and body weight had risen 4.4 percent against 16.9 percent with vehicle (PMID: 41217931). ### Pharmacokinetics in people Petrelintide injected under the skin was absorbed slowly in the two phase 1 trials, with a median time to peak concentration of 28 to 108 hours after a single dose, and its bioavailability was 77.4 percent for a 0.35 mg subcutaneous dose (PMID: 42017294). The elimination half-life was about 10 days, with means of 213 to 257 hours after single subcutaneous doses and 239 hours after an intravenous dose (PMID: 42017294). With once-weekly dosing, steady state was reached after the fifth dose, and exposure rose in proportion to dose from 0.6 to 9.0 mg (PMID: 42017294). ### Studied for - Obesity - Amylin pharmacology - Peptide drug design - Appetite regulation - Type 2 diabetes ### Benefits listed - Mean body weight change of 7.9 to 9.8 percent below baseline at 28 weeks across five doses, against 1.7 percent on placebo, in ZUPREME 1 (PMID: 42810355) - Body weight reductions of up to 10.7 percent by week 42 in ZUPREME 1 (PMID: 42810355) - Body weight 4.8 to 8.6 percent below baseline after 16 weekly doses, against 1.7 percent on placebo, in a phase 1 trial without lifestyle intervention (PMID: 42017294) - Waist circumference 5.0 to 7.6 cm smaller after 16 weeks, against 1.9 cm on placebo, in the same phase 1 trial (PMID: 42017294) Show 1 more Show less - Food intake and weight gain in diet-induced obese rats (PMID: 41217931) 02 Research Free with email ## What the research shows No research bench grades Petrelintide yet. Benches compare compounds people pair, with the evidence for each. ### Unlock the research summary Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser. - A summary of the key research - Safety and side effects - A link to the PubMed results You also get the free peptide cheat sheet by email. Unsubscribe anytime. Have an account? Sign in (https://www.bodyhackguide.co/auth) 03 Safety ## Petrelintide side effects and interactions ### Side effects #### Common - Nausea in 20 percent against 6 percent on placebo in ZUPREME 1 (PMID: 42810355) - Constipation in 7 percent against 4 percent on placebo in ZUPREME 1 (PMID: 42810355) - Diarrhea in 7 percent in both groups in ZUPREME 1 (PMID: 42810355) - Decreased appetite, reported more often than with placebo in phase 1 (PMID: 42017294) - Mild, transient injection site reactions in phase 1 (PMID: 42017294) #### Serious events - No serious or severe treatment-emergent adverse events in the two phase 1 trials (PMID: 42017294) - No deaths in ZUPREME 1 (PMID: 42810355) - Longest published treatment period 42 weeks; no data in pregnancy or children (PMID: 42810355) ### Who should not use it Contraindications Petrelintide has no approved label, so no official contraindications exist. The cautions below come from trial exclusion criteria and from what is known about the amylin drug class, and they are reported as the sources state them. Read all the contraindications and cautions Show less The phase 2 ZYNERGY trial excludes people who are pregnant or breastfeeding or who intend to become pregnant (ClinicalTrials.gov NCT07589686), and the phase 1 multiple-dose trial enrolled only women who could not become pregnant (PMID: 42017294). ZYNERGY excludes a known history or presence of pancreatitis (ClinicalTrials.gov NCT07589686). Amylin slows gastric emptying (PMID: 42586227), and ZYNERGY excludes clinically significant gastric emptying abnormalities and long-term treatment that affects gastrointestinal motility (ClinicalTrials.gov NCT07589686). ZUPREME-3 excludes current or previous treatment with petrelintide or any other amylin analog (ClinicalTrials.gov NCT07843498). No published petrelintide trial included people using insulin (PMID: 42017294, PMID: 42810355), and ZUPREME 2 excluded glucose-lowering drugs other than metformin and SGLT2 inhibitors (ClinicalTrials.gov NCT06926842). The earlier amylin analogue pramlintide, whose Symlin products Drugs@FDA lists as discontinued, carries a boxed warning that use with insulin increases the risk of severe hypoglycemia, particularly in type 1 diabetes (Symlin label). Every registered petrelintide trial enrolls adults aged 18 or older (ClinicalTrials.gov). ### Interactions 6 pairings in our record: 5 with a caution and 1 to monitor. - Cagrilintide Caution Cagrilintide is another long-acting amylin analogue that a 2026 review classifies, like petrelintide, as a dual amylin and calcitonin receptor agonist (PMID: 42452898). ZUPREME-3 excludes current or previous treatment with any other amylin analog (ClinicalTrials.gov NCT07843498), and no study has combined the two. - CagriSema Caution CagriSema contains the amylin analogue cagrilintide, and ZUPREME-3 excludes current or previous treatment with any other amylin analog (ClinicalTrials.gov NCT07843498). - Eloralintide Caution Eloralintide is another long-acting amylin-based drug in development for obesity (PMID: 42452898), and ZUPREME-3 excludes current or previous treatment with any other amylin analog (ClinicalTrials.gov NCT07843498). - Semaglutide Caution No human study has given petrelintide with semaglutide. In a laboratory stability test, the two peptides were coformulated at about neutral pH with no substantial change in petrelintide's breakdown rate and no aggregation (PMID: 41217931), which shows chemical compatibility only, not safety or effect in people. The ZYNERGY trial excludes people treated with any GLP-1-based drug in the previous 180 days (ClinicalTrials.gov NCT07589686). - Insulin Caution No published petrelintide trial included insulin users: the phase 1 trials enrolled otherwise healthy adults and ZUPREME 1 excluded type 2 diabetes (PMID: 42017294, PMID: 42810355). The earlier amylin analogue pramlintide, whose Symlin products Drugs@FDA lists as discontinued, carries a boxed warning that use with insulin increases the risk of severe hypoglycemia, particularly in type 1 diabetes (Symlin label). - Metformin Monitor ZUPREME 2 tested petrelintide in adults with type 2 diabetes taking metformin with or without an SGLT2 inhibitor; the trial is listed as completed with no posted results (ClinicalTrials.gov NCT06926842). This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. Order Bloodwork (https://anabolicinsights.ai/?ref=nwm2zjb) 04 Dosing Free with email ## Dosing No dose on record Our record lists no dose for Petrelintide. This section holds what it does list. ### Unlock the Dosing section - Route 05 Prices ## Petrelintide prices No listings We do not track a vendor for Petrelintide yet, so this page states no price. 06 Chemistry ## Chemistry and structure Molecular formula C185H305N49O61 Molecular mass 4192 g/mol CAS number 2766385-23-1 Half-life About 10 days in the 2026 phase 1 report: means of 213 to 257 hours after single subcutaneous doses and 239 hours after an intravenous dose (PMID: 42017294). In rats, 33.8 hours (PMID: 41217931). View on PubChem (https://pubchem.ncbi.nlm.nih.gov/compound/172915807) 07 Related ## Related to Petrelintide ### In the same category - AOD-9604Phase 2 AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe).: https://www.bodyhackguide.co/compound/aod-9604 - ATX-304Phase 2a Clinical Trials ATX-304 (also known as O-304) is an orally bioavailable, first-in-class pan-AMPK activator with a mild mitochondrial-uncoupling effect.: https://www.bodyhackguide.co/compound/atx-304 - CagrilintidePhase 3 Cagrilintide (also known as AM833, development code NN9838) is a long-acting amylin analog developed by Novo Nordisk as a next-generation weight-management therapy, designed to be co-administered with the GLP-1 receptor agonist semaglutide in a fixed-ratio combination known as CagriSema.: https://www.bodyhackguide.co/compound/cagrilintide - CagriSemaPhase 3 CagriSema is Novo Nordisk's once-weekly subcutaneous combination of cagrilintide, a long-acting amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 receptor agonist, developed for weight management and for type 2 diabetes.: https://www.bodyhackguide.co/compound/cagrisema - HGH Fragment 176-191Phase 2 HGH Fragment 176-191 (also written HGH Frag 176-191, hGH Fragment 176-191, and frequently appearing in clinical literature as AOD-9604 — "Anti-Obesity Drug 9604") is a synthetic peptide corresponding to the C-terminal 15-amino-acid region of the 191-amino-acid human growth hormone (hGH) molecule, with an additional N-terminal tyrosine residue added for stability and biological activity.: https://www.bodyhackguide.co/compound/hgh-frag-176-191 - LiraglutidePhase 4 Liraglutide (NN2211) is a once-daily injectable glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk: a copy of human GLP-1 with one amino acid changed and a 16-carbon fatty acid attached, which lasts about 13 hours in plasma against 1.5 to 2 minutes for the natural hormone (Victoza label; PMID: 31031702).: https://www.bodyhackguide.co/compound/liraglutide All compounds (https://www.bodyhackguide.co/wiki) ### Compare Petrelintide - Alternatives to Petrelintide: https://www.bodyhackguide.co/alternatives-to/petrelintide ### Research tools - Peptide Calculator Reconstitution and syringe units: https://www.bodyhackguide.co/tools/reconstitution - Reconstitution Guide How to mix, step by step: https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides - Nasal Spray Calc mL per actuation: https://www.bodyhackguide.co/tools/intranasal - Half-Life Visualizer Decay curves: https://www.bodyhackguide.co/tools/halflife All articles (https://www.bodyhackguide.co/blog) 08 Questions ## Frequently asked questions What is petrelintide? Petrelintide (ZP8396) is an investigational long-acting analogue of the pancreatic hormone amylin, developed by Zealand Pharma for once-weekly injection (PMID: 41217931, PMID: 42017294). Petrelintide activated the amylin 3 receptor and the calcitonin receptor at sub-nanomolar concentrations in cell assays (PMID: 41217931). Petrelintide is in phase 3 trials for weight management and is not approved by the FDA (ClinicalTrials.gov NCT07843498; Drugs@FDA, searched 27 October 2026). Who is developing petrelintide? Zealand Pharma developed petrelintide, published its design with coauthors from Boehringer Ingelheim, and sponsored its phase 1 and phase 2 trials (PMID: 41217931, PMID: 42017294, PMID: 42810355). ClinicalTrials.gov lists Hoffmann-La Roche as sponsor and Zealand Pharma as collaborator for the three phase 3 petrelintide trials, ZUPREME-3, ZUPREME-4 and ZUPREME-5 (NCT07843498, NCT07843485, NCT07843472). The Roche-sponsored petrelintide trials name the drug RO7895515 as well as ZP8396 (ClinicalTrials.gov NCT07843498, NCT07843485, NCT07843472, NCT07589686). How much weight loss was seen with petrelintide? In the 493-person ZUPREME 1 trial, mean body weight fell 7.9 to 9.8 percent from baseline at 28 weeks across five petrelintide doses, against 1.7 percent with placebo (PMID: 42810355). Body weight on petrelintide continued to fall to week 42 in ZUPREME 1, with reductions of up to 10.7 percent (PMID: 42810355). In a 16-week phase 1 trial without lifestyle intervention, petrelintide groups lost 4.8 to 8.6 percent against 1.7 percent on placebo (PMID: 42017294). What side effects were reported with petrelintide? Nausea was the most common adverse event with petrelintide in ZUPREME 1, in 20 percent of participants against 6 percent on placebo (PMID: 42810355). Vomiting in ZUPREME 1 occurred in 3 percent on petrelintide and 6 percent on placebo, and diarrhea in 7 percent of both groups (PMID: 42810355). The two phase 1 petrelintide trials reported no serious or severe treatment-emergent adverse events (PMID: 42017294). What is the half-life of petrelintide? Petrelintide had an elimination half-life of about 10 days in the phase 1 trials, with means of 213 to 257 hours after single subcutaneous doses (PMID: 42017294). Petrelintide reached steady state after the fifth once-weekly dose in the multiple-dose trial (PMID: 42017294). In rats, petrelintide had a half-life of 33.8 hours after a single injection (PMID: 41217931). How does petrelintide differ from cagrilintide? Petrelintide and cagrilintide are both long-acting amylin analogues that a 2026 review classifies as dual amylin and calcitonin receptor agonists (PMID: 42452898). Petrelintide was built on the human amylin sequence with N-methylated residues and an amide bridge so that it stays stable at neutral pH, a property its designers linked to possible coformulation with other peptides (PMID: 41217931). No registered trial compares petrelintide with cagrilintide directly, so any comparison of their effects rests on separate trials (ClinicalTrials.gov, searched 27 October 2026). Is petrelintide approved? Petrelintide is not approved by the FDA: a search of Drugs@FDA on 27 October 2026 returned no record for petrelintide, ZP8396 or RO7895515. Petrelintide entered phase 3 in 2026, with three Roche-sponsored ZUPREME trials listed as recruiting (ClinicalTrials.gov NCT07843498, NCT07843485, NCT07843472). Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) BodyHackGuide (https://www.bodyhackguide.co/) Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology). Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. - Terms: https://www.bodyhackguide.co/terms - Privacy: https://www.bodyhackguide.co/privacy ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Petrelintide" } ] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Petrelintide", "description": "Petrelintide (ZP8396) is an investigational once-weekly injectable analogue of the pancreatic hormone amylin, developed by Zealand Pharma, that activates amylin receptors and the calcitonin receptor and is in phase 3 trials for weight management (PMID: 41217931, PMID: 42017294; ClinicalTrials.gov NCT07843498). In the phase 2 ZUPREME 1 trial of 493 adults with obesity or overweight and no type 2 diabetes, mean body weight fell 7.9 to 9.8 percent from baseline across five petrelintide doses at 28 weeks against 1.7 percent with placebo, and nausea was the most common adverse event, in 20 percent against 6 percent (PMID: 42810355). Zealand Pharma funded the published trials, and ClinicalTrials.gov lists Hoffmann-La Roche as sponsor, with Zealand Pharma as collaborator, of the three phase 3 petrelintide trials (PMID: 42810355, PMID: 42017294; ClinicalTrials.gov NCT07843498, NCT07843485, NCT07843472). Petrelintide is not approved by the FDA: Drugs@FDA returned no record for petrelintide on 27 October 2026.", "lastReviewed": "2026-11-04T11:14:25.977Z", "url": "https://www.bodyhackguide.co/compound/petrelintide", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Petrelintide", "alternateName": [ "ZP8396", "RO7895515" ], "description": "Petrelintide (ZP8396) is an investigational once-weekly injectable analogue of the pancreatic hormone amylin, developed by Zealand Pharma, that activates amylin receptors and the calcitonin receptor and is in phase 3 trials for weight management (PMID: 41217931, PMID: 42017294; ClinicalTrials.gov NCT07843498). In the phase 2 ZUPREME 1 trial of 493 adults with obesity or overweight and no type 2 diabetes, mean body weight fell 7.9 to 9.8 percent from baseline across five petrelintide doses at 28 weeks against 1.7 percent with placebo, and nausea was the most common adverse event, in 20 percent against 6 percent (PMID: 42810355). Zealand Pharma funded the published trials, and ClinicalTrials.gov lists Hoffmann-La Roche as sponsor, with Zealand Pharma as collaborator, of the three phase 3 petrelintide trials (PMID: 42810355, PMID: 42017294; ClinicalTrials.gov NCT07843498, NCT07843485, NCT07843472). Petrelintide is not approved by the FDA: Drugs@FDA returned no record for petrelintide on 27 October 2026.", "activeIngredient": "Petrelintide", "administrationRoute": "Subcutaneous, Intravenous", "mechanismOfAction": "Amylin, the hormone petrelintide copies Amylin is a pancreatic beta-cell hormone released together with insulin. It contributes to blood glucose control after meals, slows gastric emptying, suppresses glucagon secretion and promotes satiation through actions in the brain (PMID: 42586227). Amylin activates amylin receptors with high potency and the calcitonin receptor with lower potency; the three amylin receptor subtypes form when the calcitonin receptor pairs with one of three receptor activity-modifying proteins (RAMPs) (PMID: 41217931). Natural human amylin is short-acting, forms amyloid fibrils and degrades in solution (PMID: 41217931). Pramlintide, the first amylin analogue approved by the FDA, in 2005, avoided fibrils by borrowing proline residues from rat amylin, must be formulated at acidic pH, and needs several injections a day because of its short half-life (PMID: 41217931). How petrelintide was designed (laboratory data) A 2025 paper by scientists at Zealand Pharma, with coauthors from Boehringer Ingelheim, describes the design (PMID: 41217931). Starting from human amylin, the team added N-methyl groups to glycine 24 and isoleucine 26, in the region that drives fibril formation, instead of using prolines (PMID: 41217931). The chemists deleted asparagines 21 and 22 and replaced other asparagines, which are prone to chemical breakdown (deamidation), to make the peptide stable at neutral pH (PMID: 41217931). The team also replaced the disulfide bridge between positions 2 and 7, which let pairs of molecules join into dimers, with an amide (lactam) bridge, and the analogues in the program carry a 20-carbon diacid attached through a gamma-glutamic acid linker at the N-terminus to extend their half-life (PMID: 41217931). Peptide 40 in the paper, the compound selected, was later named petrelintide (PMID: 41217931). Under accelerated conditions of up to 1 month at 40 degrees Celsius, petrelintide formed no fibrils and no substantial covalent oligomers in common buffers at pH 6.1 to 7.4 (PMID: 41217931). Coformulated with semaglutide at about neutral pH and stored for 4 weeks at 40 degrees Celsius, petrelintide's rate of chemical breakdown did not change substantially and neither peptide aggregated, which the authors present as support for coformulation with other peptide drugs (PMID: 41217931). Receptor activity (cell data) In COS7 cells engineered to express the human calcitonin receptor alone or together with RAMP3 (the amylin 3 receptor), petrelintide raised cyclic AMP with an EC50 of 0.33 nM at the amylin 3 receptor and 0.32 nM at the calcitonin receptor; human amylin gave 0.51 nM and 3.5 nM in the same assays (PMID: 41217931). The phase 1 report describes petrelintide as a potent agonist at the amylin 1 and amylin 3 receptors and at the calcitonin receptor (PMID: 42017294), and a 2026 review groups petrelintide with cagrilintide as a dual amylin and calcitonin receptor agonist (DACRA) (PMID: 42452898). Animal data In lean rats, a single injection under the skin gave a plasma half-life of 33.8 hours and a body weight reduction of about 10 percent 96 hours later (PMID: 41217931). In diet-induced obese rats injected every second day for 20 days, petrelintide lowered food intake in a dose-dependent way; at the highest dose, cumulative food intake by day 20 was 298 g per rat against 390 g with vehicle, and body weight had risen 4.4 percent against 16.9 percent with vehicle (PMID: 41217931). Pharmacokinetics in people Petrelintide injected under the skin was absorbed slowly in the two phase 1 trials, with a median time to peak concentration of 28 to 108 hours after a single dose, and its bioavailability was 77.4 percent for a 0.35 mg subcutaneous dose (PMID: 42017294). The elimination half-life was about 10 days, with means of 213 to 257 hours after single subcutaneous doses and 239 hours after an intravenous dose (PMID: 42017294). With once-weekly dosing, steady state was reached after the fifth dose, and exposure rose in proportion to dose from 0.6 to 9.0 mg (PMID: 42017294).", "legalStatus": "Not approved for human use (research chemical)", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is petrelintide?", "acceptedAnswer": { "@type": "Answer", "text": "Petrelintide (ZP8396) is an investigational long-acting analogue of the pancreatic hormone amylin, developed by Zealand Pharma for once-weekly injection (PMID: 41217931, PMID: 42017294). Petrelintide activated the amylin 3 receptor and the calcitonin receptor at sub-nanomolar concentrations in cell assays (PMID: 41217931). Petrelintide is in phase 3 trials for weight management and is not approved by the FDA (ClinicalTrials.gov NCT07843498; Drugs@FDA, searched 27 October 2026)." } }, { "@type": "Question", "name": "Who is developing petrelintide?", "acceptedAnswer": { "@type": "Answer", "text": "Zealand Pharma developed petrelintide, published its design with coauthors from Boehringer Ingelheim, and sponsored its phase 1 and phase 2 trials (PMID: 41217931, PMID: 42017294, PMID: 42810355). ClinicalTrials.gov lists Hoffmann-La Roche as sponsor and Zealand Pharma as collaborator for the three phase 3 petrelintide trials, ZUPREME-3, ZUPREME-4 and ZUPREME-5 (NCT07843498, NCT07843485, NCT07843472). The Roche-sponsored petrelintide trials name the drug RO7895515 as well as ZP8396 (ClinicalTrials.gov NCT07843498, NCT07843485, NCT07843472, NCT07589686)." } }, { "@type": "Question", "name": "How much weight loss was seen with petrelintide?", "acceptedAnswer": { "@type": "Answer", "text": "In the 493-person ZUPREME 1 trial, mean body weight fell 7.9 to 9.8 percent from baseline at 28 weeks across five petrelintide doses, against 1.7 percent with placebo (PMID: 42810355). Body weight on petrelintide continued to fall to week 42 in ZUPREME 1, with reductions of up to 10.7 percent (PMID: 42810355). In a 16-week phase 1 trial without lifestyle intervention, petrelintide groups lost 4.8 to 8.6 percent against 1.7 percent on placebo (PMID: 42017294)." } }, { "@type": "Question", "name": "What side effects were reported with petrelintide?", "acceptedAnswer": { "@type": "Answer", "text": "Nausea was the most common adverse event with petrelintide in ZUPREME 1, in 20 percent of participants against 6 percent on placebo (PMID: 42810355). Vomiting in ZUPREME 1 occurred in 3 percent on petrelintide and 6 percent on placebo, and diarrhea in 7 percent of both groups (PMID: 42810355). The two phase 1 petrelintide trials reported no serious or severe treatment-emergent adverse events (PMID: 42017294)." } }, { "@type": "Question", "name": "What is the half-life of petrelintide?", "acceptedAnswer": { "@type": "Answer", "text": "Petrelintide had an elimination half-life of about 10 days in the phase 1 trials, with means of 213 to 257 hours after single subcutaneous doses (PMID: 42017294). Petrelintide reached steady state after the fifth once-weekly dose in the multiple-dose trial (PMID: 42017294). In rats, petrelintide had a half-life of 33.8 hours after a single injection (PMID: 41217931)." } }, { "@type": "Question", "name": "How does petrelintide differ from cagrilintide?", "acceptedAnswer": { "@type": "Answer", "text": "Petrelintide and cagrilintide are both long-acting amylin analogues that a 2026 review classifies as dual amylin and calcitonin receptor agonists (PMID: 42452898). Petrelintide was built on the human amylin sequence with N-methylated residues and an amide bridge so that it stays stable at neutral pH, a property its designers linked to possible coformulation with other peptides (PMID: 41217931). No registered trial compares petrelintide with cagrilintide directly, so any comparison of their effects rests on separate trials (ClinicalTrials.gov, searched 27 October 2026)." } }, { "@type": "Question", "name": "Is petrelintide approved?", "acceptedAnswer": { "@type": "Answer", "text": "Petrelintide is not approved by the FDA: a search of Drugs@FDA on 27 October 2026 returned no record for petrelintide, ZP8396 or RO7895515. Petrelintide entered phase 3 in 2026, with three Roche-sponsored ZUPREME trials listed as recruiting (ClinicalTrials.gov NCT07843498, NCT07843485, NCT07843472)." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 273 compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```